Showing 21-21 of 21 Results
Pediatric Oncology Trials: ANHL2121:
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Showing 21-21 of 21 Results
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis